Galectin Therapeutics, Inc. (GALT) Analysts See $-0.13 EPS

May 14, 2018 - By Peter Erickson

Galectin Therapeutics, Inc. (NASDAQ:GALT) LogoInvestors sentiment decreased to 0.53 in Q4 2017. Its down 0.14, from 0.67 in 2017Q3. It dived, as 6 investors sold Galectin Therapeutics, Inc. shares while 13 reduced holdings. 7 funds opened positions while 3 raised stakes. 3.08 million shares or 4.50% less from 3.22 million shares in 2017Q3 were reported.
Fincl Bank Of America Corp De invested in 0% or 7,250 shares. Geode Capital Management Ltd Liability Com holds 195,411 shares or 0% of its portfolio. Cutter And Brokerage has 0.06% invested in Galectin Therapeutics, Inc. (NASDAQ:GALT). Cetera Advisor Networks Ltd Llc invested in 15,721 shares. Northern stated it has 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). The New York-based Morgan Stanley has invested 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT). California Employees Retirement System reported 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Deutsche Bankshares Ag owns 2 shares for 0% of their portfolio. Courage Llc, Tennessee-based fund reported 50,000 shares. Schwab Charles Invest Management holds 0% in Galectin Therapeutics, Inc. (NASDAQ:GALT) or 21,400 shares. Susquehanna Grp Llp invested 0% of its portfolio in Galectin Therapeutics, Inc. (NASDAQ:GALT). Blackrock Incorporated holds 198,141 shares. Buckingham Asset Management Limited Company, Missouri-based fund reported 10,000 shares. Goldman Sachs Gp reported 12,528 shares. Stratos Wealth Ltd holds 28,154 shares.

Since January 25, 2018, it had 2 buys, and 4 sales for $2.67 million activity. 244,444 shares were sold by CZIRR JAMES C, worth $1.33 million on Thursday, January 25. CALLICUTT JACK W had sold 3,349 shares worth $16,745. $1.33 million worth of Galectin Therapeutics, Inc. (NASDAQ:GALT) shares were sold by 10X Fund – L.P.. Another trade for 4,000 shares valued at $14,320 was made by ZUCCONI THEODORE DANIEL on Monday, April 16.

Analysts expect Galectin Therapeutics, Inc. (NASDAQ:GALT) to report $-0.13 EPS on May, 21.They anticipate $0.02 EPS change or 13.33 % from last quarter’s $-0.15 EPS. After having $-0.07 EPS previously, Galectin Therapeutics, Inc.’s analysts see 85.71 % EPS growth. The stock increased 5.65% or $0.19 during the last trading session, reaching $3.55. About 99,067 shares traded. Galectin Therapeutics, Inc. (NASDAQ:GALT) has risen 77.90% since May 14, 2017 and is uptrending. It has outperformed by 66.35% the S&P500.

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic disease and cancer. The company has market cap of $133.37 million. The company's lead product candidate includes galectin-3 inhibitor , a galactoarabino-rhamnogalacturonan polysaccharide polymer for the treatment of liver fibrosis and liver cirrhosis in non-alcoholic steatohepatitis patients, as well as for the treatment of cancer. It currently has negative earnings. It also engages in developing GM-CT-01, which is in pre-clinical development state for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis.

More notable recent Galectin Therapeutics, Inc. (NASDAQ:GALT) news were published by: which released: “Galectin Therapeutics Reports 2018 First Quarter Financial Results and Provides Business Update” on May 11, 2018, also with their article: “Galectin Therapeutics (GALT) Says it Will Proceed with Phase 3 Development of GR-MD-02 for NASH Cirrhosis …” published on May 14, 2018, published: “Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018” on April 18, 2018. More interesting news about Galectin Therapeutics, Inc. (NASDAQ:GALT) were released by: and their article: “Recent Analysis Shows Alphabet, Northrop Grumman, HomeStreet, Galectin Therapeutics, AZZ, and Restoration …” published on April 26, 2018 as well as‘s news article titled: “Key events next week – healthcare” with publication date: April 20, 2018.

Galectin Therapeutics, Inc. (NASDAQ:GALT) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: